key: cord-0978734-ytqjxzaa authors: Li, Yueping; Xie, Zhiwei; Lin, Weiyin; Cai, Weiping; Wen, Chunyan; Guan, Yujuan; Mo, Xiaoneng; Wang, Jian; Wang, Yaping; Peng, Ping; Chen, Xudan; Hong, Wenxin; Xiao, Guangming; Liu, Jinxin; Zhang, Lieguang; Hu, Fengyu; Li, Feng; Zhang, Fuchun; Deng, Xilong; Li, Linghua title: Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial date: 2020-05-19 journal: Med DOI: 10.1016/j.medj.2020.04.001 sha: 76d7f6bd4897e55d871b10e6b52ae2ff44216505 doc_id: 978734 cord_uid: ytqjxzaa Abstract Background Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. Methods Our study (NCT04252885, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing the efficacy and safety of lopinavir/ritonavir (LPV/r) or arbidol monotherapy for treating patients with mild/moderate COVID-19. Findings This study successfully enrolled 86 patients with mild/moderate COVID-19 with 34 randomly assigned to receive LPV/r, 35 to arbidol and 17 with no antiviral medication as control. Baseline characteristics of the three groups were comparable. The primary endpoint, the rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid, was similar between groups (all P>0.05). There were no differences between groups in the secondary endpoints, the rates of antipyresis, cough alleviation, or improvement of chest CT at days 7 or 14 (all P>0.05). At day 7, eight (23.5%) patients in the LPV/r group, 3 (8.6%) in the arbidol group and 2(11.8%) in the control group showed a deterioration in clinical status from moderate to severe/critical (P =0.206). Overall, 12 (35.3%) patients in the LPV/r group and 5 (14.3%) in the arbidol group experienced adverse events during the follow-up period. No apparent adverse event occurred in the control group. Conclusions LPV/r or arbidol monotherapy present little benefit for improving the clinical outcome of patients hospitalized with mild/moderate COVID-19 over supportive care. Funding This study was supported by project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021). Arbidol is a haemagglutinin inhibitor that can effectively block the fusion of influenza virus with its host cell. In addition, it can also induce the immune system to produce endogenous interferon against virus replication, enhance the phagocytic function of macrophages, and activate natural killer cells. 10, 11 Arbidol was reported to be effective against all strains of influenza viruses (A, B, C), especially influenza A viruses (H1N1, H2N2, H3N3), and to be safe with few side effects.12 Arbidol was also shown to have direct antiviral effects by inhibiting the replication of SARS virus in vitro.13 Despite the above preliminary evidence, the actual clinical efficacy of LPV/r or arbidol against SARS-CoV-2 are unknown. Therefore, we were urgently in need of a randomized clinical trial (RCT) to evaluate the efficacy or adverse outcomes of LPV/r or arbidol for treating COVID-19. Guangzhou Eighth People's Hospital is a designated hospital for the treatment of COVID-19 patients and over 80% of the patients confirmed with COVID-19 in Guangzhou were hospitalized at this facility. Here, we report an exploratory randomized and controlled study (ELACOI) at this hospital, aiming to provide a preliminary evaluation of the efficacy and safety of monotherapy with LPV/r or arbidol in the treatment of patients with mild/moderate COVID-19. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Linghua Li (llheliza@126.com). This study did not generate new unique reagents and did not generate new datasets. ELACOI was a single-center, randomized and controlled trial conducted at Guangzhou Eighth People's Hospital to preliminarily investigate the efficacy of LPV/r and arbidol in treating patients with COVID-19. This empirically exploratory study was initially designed to enroll 125 patients, based on the estimated number of patients admitted to the hospital. We ultimately recruited 86 patients, who were randomly assigned (2:2:1) into 3 groups as follows: In group A (LPV/r group), 34 patients were administered lopinavir (200mg) boosted by ritonavir (50mg) (orally administed, twice daily, 500 mg, each time for 7-14 days). In group B (arbidol group), 35 patients were given arbidol (100mg) (orally administed, 200mg three times daily for 7-14 days). In group C (control group), 17 patients were not given any antiviral therapy. All three groups were followed for up to 21 days. All three groups were treated with supportive care and effective oxygen therapy if in need.5 Antiviral treatment was discontinued for patients who 1) had been treated for more than 7 days and tested negative for SARS-CoV-2 nucleic acid in two consecutive tests separated by more than 24 hours, or 2) were discharged from hospital, or 3) had intolerable side effects. All participants met the following inclusion criteria: 1) age between 18 and 80 years; 2) SARS-CoV-2 infection confirmed by real-time PCR (RT-PCR) from pharyngeal swab; 3) mild clinical status, defined as having mild clinical symptoms but no signs of pneumonia on imaging or moderate clinical status, defined as having fever, respiratory symptoms and pneumonia on imaging;5 4) the following lab findings: creatinine ≤110µmol/L, creatinine clearance rate (eGFR) ≥60 ml/min/1.73m 2 , aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤5 × ULN, and total bilirubin (TBIL) ≤2 × ULN; 5) willingness to participate in the study and provide informed consent. Patients were excluded based on the following criteria: 1) known or suspected to be allergic to LPV/r or arbidol; 2) having severe nausea, vomiting, diarrhea or other complaints affecting oral intake or absorption in the digestive tract; 3) taking other drugs that may interact with LPV/r or arbidol; 4) having serious underlying diseases, including but not limited to heart, lung, or kidney disease, liver malfunction, or mental illnesses affecting treatment compliance; 5) complications with pancreatitis or hemophilia prior to the trial; 6) Pregnant or lactating women; 7) suspected or confirmed history of alcohol or substance use disorder; 8) participation in other drug trials within the past month; 9) deemed otherwise unsuitable for the study by researchers. Before initiation of the trial, the protocol was approved by the ethics committee of Guangzhou Eighth People's Hospital (Approval No. 202002136) and registered on ClinicalTrials.gov (NCT04252885). The ethics committee agreed to set up the control group owing to a lack of reliable evidence about the benefit of present antiviral regimens for treating COVID-19. The trial was also performed in accordance with the International Conference on Harmonization's Guideline for Good Clinical Practice. Written informed consent was obtained from all screened patients after they fully understood the meaning of the trial and the potential risks involved. All eligible participants were assigned a randomization number which allocated them into one treatment group. The randomization numbers were computer-generated. Allocation concealment was achieved using a centralized web-based randomization system in which the participant identifier (hospitalization number) was entered before the allocation was revealed. The randomization numbers were used in case report form (CRF) pages. The study was blinded to participants and those physicians and radiologists who reviewed the data and radiological images but open-label to clinicians who recruited patients and research staff. The primary outcome was the rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid from the initiation of treatment to day 21, with the enrollment day as the first day of treatment. The secondary outcomes were: 1) the rate of positive-to-negative conversion of SARS-CoV-2 nucleic acid at day 14; 2) the rate of antipyresis (defined as axillary temperature ≤37.3℃ for more than 72 hours) from the first day of treatment; 3) the rate of cough alleviation from initiation; 4) the improvement rate of chest CT at days 7 and 14; 5) the deterioration rate of clinical status from mild/moderate to severe/critical status during the study period. The severe status was defined as meeting any of the following criteria: experiencing respiratory distress, RR≥30 times/minute; oxygen saturation ≤93% in the resting state; arterial blood oxygen partial pressure (PaO2)/oxygen concentration (FiO2) ≤300 mmHg (1mmHg = 0.133kPa).5 The critical status was defined as meeting any of the following criteria: development of respiratory failure requiring mechanical ventilation; occurrence of shock; requirement for ICU monitoring and treatment because of complications with other organ failures.5 Specimens from pharyngeal swabs were tested every 2 to 3 days. Negative conversion of nucleic acid was defined as negative detection of SARS-CoV-2 nucleic acid for two consecutive instances separated by more than 24 hours. Criteria of chest CT improvement included: 1) no new exudative lesions; 2) decreasing size of exudative lesions; 3) decreasing densities of lesions. All participants were monitored for adverse events. Safety outcomes were assessed from serious adverse event reports. Any unexpected medical occurrence resulting in death, prolonged hospitalization, persistent or significant disability or incapacity, which was judged to be causally related to the study intervention, would be reported as a serious adverse event to the Institutional Review Board. Potential adverse events for the study were defined as follows (1) anaphylaxis; (2) elevation of ALT or AST to more than 2.5-fold the upper normal limit or elevation of TBIL to more than 1.5-fold the upper normal limit; (3) acute pancreatitis; and (4) diarrhea. The aim of this study is to explore the efficacy and safety of Lopinavir/ritonavir (LPV/r) monotherapy or arbidol monotherapy on the treatment of COVID-19 patients. However, COVID-19 is a new emerging disease without any data to provide a basis for calculating the sample size. In addition, the trend of the epidemic was not clear while we were designing the study. Based on the estimated number of patients admitted to the hospital at that time, we initially estimated that a maximum of 125 patients could meet the inclusion criteria, however, only 86 were ultimately recruited because few new cases developed in Guangzhou with the epidemic under control. All statistical analyses were performed using SPSS (Statistical Package for SPSS, version 26.0). We presented continuous measurements as mean (SD) if the data were normally distributed or median (IQR) if they were not, and categorical variables as count (%). Means for continuous variables were compared using one-way ANOVA when the data were normally distributed; otherwise, the Mann-Whitney test was used. Proportions for categorical variables were compared using the χ 2 test or Fisher's exact tests. A two-sided α of less than 0.05 was considered statistically significant. During the study period, six patients used gamma globulin (10 g, once a day, for 2-3 days),12 used glucocorticoids (methylprednisolone 40 mg, once a day, for 3-5 days) and 54 received oxygen supply therapy. The usage percentages of the above supportive treatment did not show statistical differences between the three groups (P=0.865, P=0.153, P=0.677 respectively). The With respect to other secondary outcomes, the rate of antipyresis, rate of cough resolution, and rate of improvement on chest CT imaging at day 7 and 14 did not show any statistical difference between the three groups (P > 0.05). Our study is not without its limitations. First, we recognize that our sample size was small. Second, the study did not enroll severely or critically ill patients, or patients at increased risk of poor outcome with many comorbidities and was conducted in only one center. Third, the study was not completely blinded, possibly influencing the outcome to some extent. We will continue to follow these patients to evaluate their long-term prognosis. Nevertheless, as a prospective randomized, controlled trial, this study could still provide meaningful suggestions for proper application of LPV/r and arbidol in the treatment of COVID-19. In conclusion, our study found that LPV/r or arbidol monotherapy presents little benefit for improving the clinical outcome of hospitalized patients with mild/moderate COVID-19 beyond symptomatic and supportive care, causing instead more adverse events. Further work is needed to confirm these results. Chen, Wenxin Hong and Guangming Xiao contributed to conducting the study and collecting data. We declare no competing interests. hypertension and 2 with both in the LPV/r group; one patient with Coronary Heart Disease, 3 with hypertension and 1 with chronic liver disease in the arbidol group; and one patient with Coronary Heart Disease, 2 with hypertension, 2 with chronic liver disease and 1 with both diabetes and chronic liver disease in the control group. Several drugs are being tested against the novel coronavirus SARS-CoV-2, the pathogen responsible for the COVID-19 pandemic. Li et al show that the drugs lopinavir/ritonavir and arbidol, which are currently used against HIV-1 and influenza, respectively, show little benefit over supportive care in patients with mild and moderate COVID-19. • Effective therapies effective against COVID-19 are urgently needed • Lopinavir/ritonavir and arbidol were tested in patients with mild/moderate COVID-19 • Neither treatment shows significant advantage over supportive care The coronavirus SARS-CoV-2 is causing the current COVID-19 pandemic, which has affected over 1 million people worldwide. As the scientific community researches new treatments against the disease, drugs that have already been approved for other viruses are also being tested. Here, clinicians from Guangzhou Medical University here tested lopinavir/ritonavir and arbidol, which are currently used against HIV-1 and influenza, respectively, in patients with mild or moderate COVID-19. The authors show that neither drug improves the recovery compared to standard care, suggesting that treatment with either drug may not be beneficial against COVID-19 and other therapies may be a more effective choice. Clinical Features of Cases with Coronavirus Disease Coronavirus disease 2019 331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_8. Date last updated Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions Time course of changes in cytokines (IFN-γ, IFN-α, IL-18, TNF-α) in the treatment of moderate influenza A (H1N1) pdm09 (2013-2016) with oseltamivir (Tamiflu) and umifenovir (Arbidol) alone and in combination with Kagocel Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity Clinical trial analysis of 2019-nCoV therapy registered in China A rapid advice guideline for the diagnosis and treatment of clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-infected Pneumonia in Wuhan Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. (In Chinses) This study was supported by Chinese 13th Five-Year National Science and technology major project(2018ZX10302103-002, 2017ZX10202102-003-004),